DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
Damian Wild(University Hospital of Basel), Jean–Claude Reubi(University of Bern), Jörg Schmitt(University Hospital of Basel), Bert F. Bernard(Rotterdam University of Applied Sciences), Marion de Jong(Erasmus MC), Sandra Wenger(University of Bern), Eric P. Krenning(Cyclotron (Netherlands)), Helmut R. Mäcke(University Medical Center Freiburg), Mihaela Ginj(University Hospital of Basel)
Cited by 301
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814